652: Invade or Proliferate? A Comparative Analysis of Expression of Cell Cycle Regulators in Invasive Margin and Primary Tumor Tissue in Renal Cell Cancer

2005 ◽  
Vol 173 (4S) ◽  
pp. 178-178
Author(s):  
Stephen O. Ikuerowo ◽  
Stefan A. Machtens ◽  
Markus A. Kuczyk ◽  
Udo Jonas ◽  
Juergen Serth
Keyword(s):  
Cell Cycle ◽  
Comparative Analysis ◽  
Renal Cell Cancer ◽  
Primary Tumor ◽  
Renal Cell ◽  
Tumor Tissue ◽  
Cell Cancer ◽  
Cell Cycle Regulators ◽  
Invasive Margin

Immunotherapy for Metastatic Renal Cell Cancer: Effect on the Primary Tumor

1993 ◽  
Vol 13 (2) ◽  
pp. 130-135 ◽  
Author(s):  
Gabriel P. Haas ◽  
Bruce G. Redman ◽  
Vasantha K. Rao ◽  
Eric Dybal ◽  
J Edson Pontes ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Primary Tumor ◽  
Renal Cell ◽  
Cell Cancer ◽  
Metastatic Renal Cell Cancer

A multigene expression score for predicting response to anti-PD-1/PD-L1 therapy for clear cell renal cell cancer patients.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 656-656
Author(s):  
Yukti Choudhury ◽  
Kai Wei Tan ◽  
Hui Shan Tan ◽  
Jian Cheng Hong ◽  
Miah Hiang Tay ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Clinical Benefit ◽  
Renal Cell ◽  
Tumor Tissue ◽  
Clear Cell ◽  
Cell Cancer ◽  
Cell Infiltration ◽  
Potential Biomarker ◽  
Cd8 Cell ◽  
Expression Score

656 Background: Anti-PD-1 inhibitor nivolumab and combination checkpoint inhibition (nivolumab and ipilimumab) are approved for advanced clear cell renal cell cancer (ccRCC), with objective response rates between 25% to 40%. PD-L1 expression is a poor predictor of anti-PD-1/PD-L1 therapy response in ccRCC. Better predictive biomarkers are required. The CLEAR score (CS) is a multigene prognostic expression score for ccRCC (Eur Urol 2015) previously associated with TKI outcomes. Given association of prognosis and clinical benefit, CS was explored as a biomarker for response to anti-PD-1/PD-L1 therapy in this study. Methods: CS is derived from the expression of 8 genes in ccRCC tumor tissue and intervening stroma and includes components of chemokine signaling. Based on this, immunohistochemistry of ccRCC tumor tissue (n = 24; matched CS also derived from same tissue), was done for tumor-infiltrating lymphocytes (CD8+) and PD-L1. Staining intensity was also correlated to CS. In another set of RCC patients who received nivolumab or pembrolizumab after progression on anti-angiogenic therapy (n = 12), correlation of their tumor CS and response outcome to anti-PD-1 therapy was done. Results: CS was significantly higher for ccRCC tumors with higher intratumor and/or stromal CD8+ cell infiltration (p < 0.001). A similar correlation with PD-L1 staining was not observed. Among RCC patients receiving anti-PD-1 therapy, clinical benefit (stable disease or partial response) was characterized by higher CS, regardless of treatment line. When analysis was limited to ccRCC histology, CS were significantly higher (p < 0.05) for responders (n = 2) compared to non-responders (n = 4) to nivolumab treatment. Conclusions: This is the first study reporting the correlation of a multi-gene score (CS) with immune phenotypes in ccRCC. CS correlates well with intratumor/stromal CD8+ cell infiltration, and is a potential biomarker for response to anti-PD-1 therapy. Consistent with clinical trial data, high CS (associated with poor prognostic tumors) correlated with better responses. Studies with a larger cohort of patients are underway to establish the utility of CS in predicting response to anti-PD-1/PD-L1 therapy.

scholarly journals Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response

2008 ◽  
Vol 14 (8) ◽  
pp. 2431-2436 ◽  
Author(s):  
Astrid A.M. van der Veldt ◽  
Martijn R. Meijerink ◽  
Alfons J.M. van den Eertwegh ◽  
Axel Bex ◽  
Gijsbert de Gast ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Primary Tumor ◽  
Renal Cell ◽  
Tumor Response ◽  
Cell Cancer ◽  
Advanced Renal Cell Cancer

scholarly journals FOXM1 participates in PLK1-regulated cell cycle progression in renal cell cancer cells

2016 ◽  
Vol 11 (4) ◽  
pp. 2685-2691 ◽  
Author(s):  
ZHE ZHANG ◽  
GUOJUN ZHANG ◽  
CHUIZE KONG
Keyword(s):  
Cell Cycle ◽  
Cancer Cells ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cycle Progression ◽  
Cell Cancer ◽  
Cycle Progression

scholarly journals Primary Tumor Size in Renal Cell Cancer in Relation to the Occurrence of Synchronous Metastatic Disease

2014 ◽  
Vol 92 (4) ◽  
pp. 462-467 ◽  
Author(s):  
Stefan Zastrow ◽  
Anh Phuong ◽  
Immanuel von Bar ◽  
Vladimir Novotny ◽  
Oliver W. Hakenberg ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Metastatic Disease ◽  
Tumor Size ◽  
Primary Tumor ◽  
Renal Cell ◽  
Cell Cancer ◽  
Primary Tumor Size

644: Cathepsin D is a Marker for Early Stage Renal Cell Cancer and Predicts the Presence of Distant Metastases

2005 ◽  
Vol 173 (4S) ◽  
pp. 175-175
Author(s):  
Axel S. Merseburger ◽  
Joerg Hennenlotter ◽  
Perikles Simon ◽  
Marcus Horstmann ◽  
Arnulf Stenzl ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cathepsin D ◽  
Early Stage ◽  
Cell Cancer ◽  
Distant Metastases

361: Serum Levels of Angiogenin and Vascular Endothelial Growth Factor (VEGF) Predict Metastatic Disease in Renal Cell Cancer Patients

2005 ◽  
Vol 173 (4S) ◽  
pp. 99-99 ◽  
Author(s):  
Marcus Horstmann ◽  
Axel S. Merseburger ◽  
Markus A. Kuczyk ◽  
Arnulf Stenzl ◽  
Karl-Horst Bichler ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Patients ◽  
Renal Cell Cancer ◽  
Metastatic Disease ◽  
Renal Cell ◽  
Cell Cancer ◽  
Serum Levels ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Surgery for Renal Cell Cancer Involving the Inferior Vena Cava

1998 ◽  
Vol 6 (1) ◽  
pp. 51-72
Author(s):  
Allan J. Pantuck ◽  
Kenneth B. Cummings
Keyword(s):  
Inferior Vena Cava ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Inferior Vena ◽  
Cell Cancer ◽  
Vena Cava

Gene Signatures of Progression and Metastasis in Renal Cell Cancer

2006 ◽  
Vol 37 (S 1) ◽  
Author(s):  
J Jones ◽  
H Otu ◽  
D Spentzos ◽  
S Kolia ◽  
R Blaheta ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Gene Signatures
Sign in / Sign up

Export Citation Format

Share Document